STADA: Earnings 2016 slightly above expectations – Growth to continue in 2017
- 3/1/2017
- Investor News
- Press Release
- Adjusted net income +11 percent
- Significant improvement of Generics margin
- Accelerated sales and earnings growth of Branded Products in Q4
- Cash flow from operating activities increased significantly
- Further reduction of net debt – net debt to adjusted EBITDA ratio improved to 2.8
- Dividend proposal of Euro 0.72 per share (previous year: Euro 0.70)
Preliminary STADA Group key figures
|
2016 |
2015 |
+/- |
Q4/2016 |
Q4/2015 |
+/- |
Group sales, reported |
€ 2,151.7 million |
€ 2,115.1 million |
+2% |
€ 610.0 million |
€ 581.6 million |
+5% |
Group sales, adjusted |
€ 2,180.0 million |
€ 2,100.4 million |
+4% |
€ 611.6 million |
€ 578.3 million |
+6% |
EBITDA, reported |
€ 369.3 million |
€ 377.1 million |
-2% |
€ 80.2 million |
€ 95.9 million |
-16% |
EBITDA, adjusted |
€ 405.7 million |
€ 389.4 million |
+4% |
€ 105.1 million |
€ 95.6 million |
+10% |
Net income, reported |
€ 92.9 million |
€ 110.4 million |
-16% |
€ -7.4 million |
€ 20.5 million |
>-100% |
Net income, adjusted |
€ 184.3 million |
€ 165.8 million |
+11% |
€ 44.4 million |
€ 38.9 million |
+14% |
Earnings per share, reported |
€ 1.49 |
€ 1.79 |
-17% |
€ -0.12 |
€ 0.33 |
>-100% |
Earnings per share, adjusted |
€ 2.96 |
€ 2.69 |
+10% |
€ 0.71 |
€ 0.62 |
+14% |
Dividend (proposed 2016) |
€ 0.72 |
€ 0.70 |
+3% |
-- |
-- |
-- |
All figures included in this investor news are preliminary and not yet audited.
Bad Vilbel, March 1, 2017 –
Increase of dividend proposed
Despite the decrease in reported net income, in light of STADA’s dividend policy, which has been consistent for decades, the Executive Board is recommending to the Supervisory Board that a dividend of Euro 0.72 per share is proposed for financial year 2016 at the next Annual General Meeting on June 8, 2017 (previous year: Euro 0.70). This would represent an increase in the dividend of 3 percent compared to the prior year. The resulting total dividend payment of Euro 44.8 million (previous year: Euro 43.6 million) would reflect a distribution ratio of approximately 48 percent of reported net income.
Significant increase in cash flow from operating activities
Cash flow from operating activities amounted to Euro 333.5 million in financial year 2016 (previous year: Euro 311.7 million). Free cash flow was at Euro 160.9 million (previous year: Euro 133.5 million). Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals amounted to Euro 243.0 million (previous year: Euro 212.4 million).
Net debt reduced
Net debt was reduced to Euro 1,118.2 million as of the reporting date (December 31, 2015: Euro 1,215.7 million). The net debt to adjusted EBITDA ratio improved to 2.8 in 2016 (previous year: 3.1).
Outlook for financial year 2017
For financial year 2017, the Executive Board expects Group sales of between Euro 2.280 and 2.350 billion, adjusted for currency and portfolio effects with an adjusted EBITDA between Euro 430 and 450 million and adjusted net income between Euro 195 and 205 million.
STADA will publish the final figures for financial year 2016 as part of the press and analysts’ conference on March 23, 2017.
Preliminary STADA segment key figures Generics
|
2016 |
2015 |
+/- |
Q4/2016 |
Q4/2015 |
+/- |
Sales, reported |
€ 1,290.1 million |
€ 1,261.4 million |
+2% |
€ 358.3 million |
€ 333.2 million |
+8% |
Sales, adjusted |
€ 1,297.0 million |
€ 1,253.2 million |
+3% |
€ 352.7 million |
€ 331.5 million |
+6% |
EBITDA, reported |
€ 261.7 million |
€ 233.2 million |
+12% |
€ 68.9 million |
€ 73.2 million |
-6% |
EBITDA, adjusted |
€ 270.8 million |
€ 232.0 million |
+17% |
€ 77.3 million |
€ 71.4 million |
+8% |
Margin, reported |
20.3% |
18.5% |
|
19.2% |
22.0% |
|
Margin, adjusted |
21.0% |
18.4% |
|
21.6% |
21.4% |
|
Reported sales of the Generics segment grew by 2 percent to of Euro 1,290.1 million in the reporting year (previous year: Euro 1,261.4 million). Sales of the Generics segment adjusted for portfolio effects and currency influences increased by 3 percent to Euro 1,297.0 million (previous year: Euro 1,253.2 million). Generics contributed 60.0 percent to Group sales (previous year: 59.7 percent).
Preliminary STADA segment key figures Branded Products
|
2016 |
2015 |
+/- |
Q4/2016 |
Q4/2015 |
+/- |
Sales, reported |
€ 861.6 million |
€ 853.6 million |
+1% |
€ 251.7 million |
€ 248.2 million |
+1% |
Sales, adjusted |
€ 883.0 million |
€ 847.1 million |
+4% |
€ 258.8 million |
€ 246.7 million |
+5% |
EBITDA, reported |
€ 188.0 million |
€ 211.8 million |
-11% |
€ 30.1 |
€ 40.3 million |
-25% |
EBITDA, adjusted |
€ 202.4 million |
€ 220.1 million |
-8% |
€ 41.3 million |
€ 38.7 million |
+7% |
Margin, reported |
21.8% |
24.8% |
|
12.0% |
16.2% |
|
Margin, adjusted |
23.5% |
25.8% |
|
16.4% |
15.6% |
|
Reported sales of the Branded Products segment increased by 1 percent to Euro 861.6 million in financial year 2016 (previous year: Euro 853.6 million). Sales of the Branded Products segment adjusted for portfolio effects and currency influences increased by 4 percent to Euro 883.0 million (previous year: Euro 847.1 million). Branded products contributed 40.0 percent to Group sales (previous year: 40.3 percent).
Preliminary STADA reconciliation – Preliminary special items 2016
in € million1 |
2016 |
Impair-ments/ |
Effects from |
Currency translation |
Measurement of derivative |
Portfolio adjust-ments/Re-structuring expenses4 |
Other5 |
2016 adjusted |
Earnings before interest, taxes, depreciation and amortiza-tion (EBITDA) |
369.3 |
-- |
-2.9 |
9.1 |
-- |
28.2 |
2.0 |
405.7 |
Balance from deprecia-tion/amortiza-tion and impairments/ write-ups on intangible assets (including goodwill), property, plant and equipment and financial assets |
182.7 |
-65.5 |
-14.3 |
-- |
-- |
-- |
-- |
102.9 |
Financial income and expenses |
51.4 |
-- |
-- |
-- |
-0.5 |
-- |
-- |
50.9 |
Income taxes |
32.7 |
12.8 |
3.1 |
1.1 |
0.1 |
5.3 |
4.0 |
59.1 |
Result distributable to non-controlling shareholders |
9.6 |
0.5 |
-1.6 |
-- |
-- |
-- |
-- |
8.5 |
Result distributable to |
92.9 |
52.2 |
9.9 |
8.0 |
0.4 |
22.9 |
2.0 |
184.3 |
1 As a result of the presentation in € million, deviations due to rounding may occur in the tables.
2 Relates to additional scheduled depreciation and other measurement effects due to purchase price allocations as well as significant product acquisitions taking financial year 2013 as basis.
3 Relates to currency translation effects recorded in the income statement resulting from the fluctuation of the Russian ruble as well as other significant currencies of the region CIS/Eastern Europe.
4 Relates to miscellaneous extraordinary expenses, among other things, for the restructuring of the Germany business, the termination of main parts of the Aesthetics business, expenses in connection with the deconsolidation of the Egyptian subsidiary as well as the termination of a distribution agreement in Belgium.
5 Relates to miscellaneous extraordinary income and expenses, among other things, from a milestone payment received in the United Kingdom, tax rate changes in the United Kingdom as well as a severance payment for the former Chairman of the Executive Board.
Contact:
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de